Inhibition of Ras prenylation: A signaling target for novel anti-cancer drug design

Anti-Cancer Drug Design

Volumn 12, Issue 4, 1997, Pages 229-238

  Lerner, Edwina C ^a   Hamilton, Andrew D ^b   Sebti, Saïd M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIMETHYLALLYLTRANSFERASE; GERANYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; ONCOGENE RAS; PRENYLATION; PRIORITY JOURNAL; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; DIMETHYLALLYLTRANSTRANSFERASE; DRUG DESIGN; FARNESYLTRANSTRANSFERASE; HUMANS; MICE; PROTEIN ISOPRENYLATION; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSFERASES;

EID: 0031007684     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. BARBACID, M. (1987). ras genes. Annual Review of Biochememistry, 56, 779.
2. BERNHARD, E.J., KAO, G., COX., A.D , SEBTI, S M., HAMILTON, A.D., MUSCHEL, R J. & MCKENNA, W.G (1996). The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Research, 56, 1727.
3. BHIDE, R S , PATEL, D V , PATEL, M M., ROBINSON, S.P., HUNIHAN, L.W & GORDON, E.M. (1994). Rational design Of potent carboxylic acid based bisubstrate inhibitors of Ras farnesyl protein transferase. Bioorganic and Medicinal Chemistry Letters, 4, 2107.
4. BISHOP, W.R., BOND, R., PETRIN, J., WANG, L., PATTON, R., DOLL, R., NJOROGE, G., CATINO, J., SCHWARTZ, J. & WINDSOR, W. (1995). Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells. Journal of Biological Chemistry, 270, 30611.
5. BUSS, J.E. & MARSTERS, J C., JR (1995). Farnesyltransferase inhibitors: the successes and surprises of a new class of potential cancer chemotherapeutics. Chemical Biology, 2, 787.
6. CASEY, P. J. (1992). Biochemistry of protein prenylation. Journal of Lipid Research, 33, 1731.
7. CASEY P.J., SOLSKI, P.A., DER, C.J & BUSS, J E. (1989). P21ras is modified by a farnesyl isoprenoid. Proceedings of the National Academy of Sciences, USA, 86, 8323.
8. COX, A.D., GARCIA, A.M., WESTWICK, J.K., KOWALCZYK, J.J., LEWIS, M D., BRENNER, D.A. & DER, C.J. (1994). The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic Ras signaling and transformation. Journal of Biological Chemistry, 269, 19203.
9. GARCIA, A.M., ROWELL, C., ACKERMANN, K., KOWALCZYK, J.J & LEWIS, M.D. (1993). Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. Journal of Biological Chemistry, 268, 18415.
10. GIBBS, J.B., OLIFF, A. & KOHL, N E (1994). Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell, 77, 175.
11. GRAHAM, S.L., DESOLMS, S.J., GIULIANI, E.A., KOHL, N.E., MOSSER, S.D., OLIFF, A.I., POMPLIANO, D.L., RANDS, E., BRESLIN, M J , DEANA, A A., GARSKY, V M., SCHOLZ, T.H., GIBBS, J.B & SMITH, R.L (1994). Pseudopeptide inhibitors of Ras farnesyl-protein transferase. Journal of Medicinal Chemistry, 37, 725.
12. HANCOCK, J.F., MAGEE, A.I., CHILDS, J.E. & MARSHALL, C.J. (1989). All Ras proteins are polyisoprenylated but only some are palmitoylated. Cell, 57, 1167.
13. HANCOCK, J.F., PATERSON, H. & MARSHALL, C.J. (1990). A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell, 63, 133.
14. HARRINGTON, E M., KOWALCZYK, J.J , PINNOW, S.L., ACKERMANN, K., GARCIA, A M. & LEWIS, M.D. (1994). Cysteine and methionine linked by carbon pseudopeptides inhibit farnesyl transferase. Bioorganic and Medicinal Chemistry Letters, 4, 2775.
15. HUNT, J T., LEE, V.G , LEFTHERIS, K., SEIZINGER, B., CARBONI, J , MABUS, J., RICCA, C., YAN, N. & MANNE, V. (1996). Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. Journal of Medicinal Chemistry, 39, 353.
16. JACKSON, J H , COCHRANE, C.G., BOURNE, J.R., SOLSKI, P.A., BUSS, J E & DER, C J (1990). Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proceedings of the National Academy of Sciences, USA, 87, 3042.
17. JAMES, G.L., GOLDSTEIN, J.L., BROWN, M.S., RAWSON, T.E , SOMERS, T.C., MCDOWELL, R S., CROWLEY, C.W., LUCAS, B K , LEVINSON, A.D. & MARSTERS, J.C , JR (1993). Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science, 60, 1937.
18. JAMES, G.L., BROWN, M S., COBE, M.H. & GOLDSTEIN, G.L (1994). Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-ras-transformed rat-1 cells, but not in untransformed cells. Journal of Biological Chemistry, 269, 27705.
19. JAMES, G L., GOLDSTEIN, J.L. & BROWN, M S (1995). Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. Journal of Biological Chemistry, 270, 6221.
20. KATO, K., COX., A.D., HISAKA, M.M , GRAHAM, S M , BUSS, J.E. & DER, C J (1992). Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proceedings of the National Academy of Sciences, USA, 89, 6403.
21. KAUFFMANN, R.C , QIAN, Y., VOGT, A., SEBTI, S.M., HAMILTON, A D. & CARTHEW, R W (1995). Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proceedings of the National Academy of Sciences, USA, 92, 10919.
22. KOHL, N.E., MOSSER, S D., DESSOLMS, S.J., GIULIANI, E A., POMPLIANO, D.L., GRAHAM, S.L , SMITH, R.L., SCOLNICK, E.M., OLIFF, A, & GIBBS, J.B. (1993). Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science, 260, 1934.
23. KOHL, N.E., WILSON, F.R., MOSSER, S.D., GIULIANI, E., DESOLMS, S.J., CONNER, M.W., ANTHONY, N.J., HOLTZ, W.J., GOMEZ, R.P., LEE, T.J., SMITH, R.L., GRAHAM, S.L., HARTMAN, G., GIBBS, J.B. & OLIFF, A. (1994). Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proceedings of the National Academy of Sciences, USA, 91, 9141.
24. KOHL, N.E., CONNER, M.W , GRIBBS, J.B., GRAHAM, S.L., HARTMAN, G.D. & OLIFF, A. (1995a). Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. Journal of Cellular Biochemistry, 22, 145.
25. KOHL, N.E., OMER, C.A., CONNER, M.W., ANTHONY, N.J., DAVIDE, J.P., DESOLMS, S.J., GUILIANI, E.A , GOMEZ, R P., GRAHAM, S.L., HAMILTON, K., HANDT, L K., HARTMAN, G.-D , KOBLAN, K.S., KRAL, A.M., MILLER, P.J., MOSSER, S.O., O'NEILL, T.J., RANDS, E., SCHABER, M.D., GIBES, J B & OLIFF, A. (1995b). Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Medicine, 1, 792.
26. LERNER, E.C., QIAN, Y., HAMILTON, A.D. & SEBTI, S.M. (1995a). Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. Journal of Biological Chemistry, 270, 26770.
27. LERNER, E C., QIAN, Y, BLASKOVICH, M A , FOSSUM, R.D , VOGT, A , SUN, J., COX, A.D., DER, C.J., HAMILTON, A.D. & SEBTI, S.M. (1995b). Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. Journal of Biological Chemistry, 270, 26802.
28. LERNER, E.C., ZHANG, T.T., KNOWLES, D , QIAN, Y, HAMILTON, A.D. & SEBTI, S.M. (1997). Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene, in press.
29. MANNE, V , YAN, N , CARBONI, J.M., TUOMARI, A.V , RICCA, C.S., BROWN, J.G., ANDAHAZY, M.L., SCHMIDT, R.J., PATEL, D & ZAHLER, R. (1995). Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Oncogene, 10, 1763.
30. MCCORMICK, F. (1993). How receptors turn Ras on. Nature, 363, 15.
31. MCGUIRE, T.F., QIAN, Y., BLASKOVICH, M A , FOSSUM, R.D., SUN, J., MARLOWE, T. COREY, S.J., WATHEN, S.P., VOGT, A., HAMILTON, A.D. & SEBTI, S M (1995). CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. Biochemical and Biophysical Research Communications, 214, 295.
32. MCGUIRE, TF, QIAN, Y, VOGT, A., HAMILTON, A.D. & SEBTI, S M (1996). Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. Journal of Biological Chemistry, 271, 27402.
33. MIQUEL, K , PRADINES, A., SUN, J., QIAN, Y., HAMILTON, A.D. SEBTI, S M & FAURE, G. (1997). GGTI-298 induces 60/61 block and apoptosis whereas FTI-277 causes 62/M enrichment in A549 cells. Cancer Research, in press.
34. MOOMAW, J F. & CASEY, P.J (1992). Mammalian protein geranylgeranyltransferase. Subunit composition and metal requirements. Journal of Biological Chemistry, 267, 17438.
35. NAGASU, T., YOSHIMATSU, K , ROWELL, C , LEWIS, M D. & GARCIA, A.M. (1995). Inhibition of human tumor xenograft growth by treatment with farnesyltransferase inhibitor B956. Cancer Research, 55, 5310.
36. NIGAM, M., SEONG, C.M., QIAN, Y., HAMILTON, A.D. & SEBTI, S.M (1993). Potent inhibition of human tumor p21 ras farnesyltransferase by A1 A2-lacking p21 ras CA1A2X peptidomimetics. Journal of Biological Chemistry, 268, 20695.
37. PATEL, D V , GORDON, E.M., SCHMIDT, R.J., WELLER, H.N., YOUNG, M.G., ZAHLER, R , BARBACID, M , CARBONI, J M., GULLO-BROWN, J.L , HUNIHAN, L., RICCA, C., ROBINSON, S., SWIZINGER, B.R , TUOMARI. A V. & MANNE, V. (1995). Phosphinyl acid-based bisubstrate analog inhibitors of farnesyl protein transferase. Journal of Medicinal Chemistry, 38, 435.
38. QIAN, Y., BLASKOVICH, M A., SALEEM, M., SEONG, C.M., WATHEN, S.P. HAMILTON, A.D & SEBTI, S.M. (1994a). Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase. Journal of Biological Chemistry, 269, 12410.
39. QIAN, Y., BLASKOVICH, M.A., SEONG, C.-M., VOGT, A., HAMILTON, A.D. & SEBTI, S.M (1994b). Peptidomimetic inhibitors of p21ras farnesyltransferase: hydrophobia functionalization leads to disruption of p21 ras membrane association in whole cells. Bioorganic and Medicinal Chemistry Letters, 4, 2579.
40. QIAN, Y., VOGT, A., SEBTI, S.M. & HAMILTON, A D. (1996). Design and synthesis of non-peptide ras CAAX mimetics as potent farnesyltransferase inhibitors. Journal of Medicinal Chemistry, 39, 217.
41. REISS, Y, GOLDSTEIN, J.L , SEABRA, M C, CASEY, P.J. & BROWN, M.S. (1990). Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62, 81.
42. REISS, Y., SEABRA, M.C., ARMSTRONG, S.A., SLAUGHTER, C.A., GOLDSTEIN, J.L. & BROWN, M.S (1991). Nonidentical subunits of p21H-Ras farnesyltransferase. Journal of Biological Chemistry, 266, 10672.
43. SATTLER, I & TAMANOI, F. (1996). Prenylation of ras and inhibitors of prenyltransferases. In Regulation of the Ras Signaling Network, Molecular Biological Intelligence Unit Series. Maruta, H. & Burgess, A.W. (eds), p. 95. R.G. Landers: Austin, TX.
44. SEABRA, M C , REISS, Y., CASEY, P.J., BROWN, M.S. & GOLDSTEIN, J.L (1991). Protein farnesyltransferase and geranylgeranyltransferase share a common α-subunit. Cell, 65, 429.
45. SEBOLT-LEOPOLD, J S., GOWAN, R.C , SCHOLTEN, J , CRESWELL, M & BOLTON, G.L (1995). Synthesis and evaluation of novel tri- and dipeptide inhibitors of ras farnesyl protein transferase. 86th Annual Meeting of American Association for Cancer Research, Toronto, Canada, Abstract no. 2561.
46. SEBTI, S M & HAMILTON, A.D. (1997). Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacology and Therapeutics, in press.
47. SEPP-LORENZINO, L., MA, Z., RANDS, E , KHOL, N.E., GIBBS, J.B., OLIFF, A & ROSEN, N (1995). A peptidomimetic inhibitor of farnesyltransferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Research, 55, 5302.
48. SUN, J , QIAN, Y., HAMILTON, A.D & SEBTI, S.M (1995). Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Research, 55, 4243.
49. TAMANOI, F. (1993). Inhibitors of Ras farnesyltransferase. Trends in Biochemical Science, 18, 349.
50. TRUEBLOOD, C.E., OHYA, Y & RHINE, J. (1993). Genetic evidence for in vivo cross-specificity of the CAAX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase I in Saccharomyces cerevisiae. Molecular and Cellular Biology, 13, 4260.
51. VOGT, A., QIAN, Y., BLASKOVICH, M A , FOSSUM, R.D., HAMILTON, A D. & SEBTI, S.M. (1995). A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. Journal of Biological Chemistry, 270, 660.
52. 1 to S transition in mouse fibroblasts. Oncogene, 13, 1991.
53. WILLIAMS, T.M., CICCARONE, T M., MACTOUGH, S.C., BOCK, R.L , CONNER, M W, DAVIDE, J P, HAMILTON, K., KOBLAN, K S , KOHL, E.E , KRAL, A M., MOSSER, S.D , OMER, C. A., POMPLIANO, D L , RANDS, E., SCHABER, M.D., SHAH, D., WILSON, F.R., GIBBS, J.B., GRAHAM, S.L., HARTMAN, G.D., OLIFF, A I & SMITH, R.L. (1996). 2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase. Journal of Medicinal Chemistry, 39, 1345.
54. YOKOYAMA, K., GOODWIN, G W., GHOMASHCHI, F., GLOMSET, J.A. & GELB, M.H (1991). A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity. Proceedings of the National Academy of Sciences, USA, 88, 5302.
55. ZHANG, F L , DIEHL, R.E., KHOL, N.E., GIBBS, J.B , GIROS, B., CASEY, P.J. & OMER, C A. (1994). cDNA cloning and expression of rat and human protein geranylgeranyl transferase type-I. Journal of Biological Chemistry, 269, 3175.